

# Collen Mutowembwa Masimirembwa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4336477/publications.pdf>

Version: 2024-02-01

58  
papers

1,973  
citations

318942

23  
h-index

286692

43  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2730  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 173-182.	0.7	10
2	Clinically relevant enantiomer specific Râ€•and Sâ€•praziquantel pharmacokinetic drugâ€•drug interactions with efavirenz and ritonavir. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00769.	1.1	5
3	CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populationsâ€•Implication for Drug Safety, Dosing, and Individualized Therapy. <i>Frontiers in Genetics</i> , 2021, 12, 692234.	1.1	35
4	In vitro and in vivo human metabolism and pharmacokinetics of Sâ€•and Râ€•praziquantel. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00618.	1.1	12
5	A review of clinical pharmacogenetics Studies in African populations. <i>Personalized Medicine</i> , 2020, 17, 155-170.	0.8	35
6	Spatial distribution of Mycobacterium Tuberculosis in metropolitan Harare, Zimbabwe. <i>PLoS ONE</i> , 2020, 15, e0231637.	1.1	15
7	An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T&gt;C and ABCG2 c.421A&gt;C. <i>Pharmacogenomics Journal</i> , 2019, 19, 240-248.	0.9	12
8	The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1077-1087.	0.8	14
9	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenzâ€•Containing Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 726-733.	2.3	125
10	African Pharmacogenomics Consortium:Â•Consolidating pharmacogenomics knowledge, capacity development and translation in Africa. <i>AAS Open Research</i> , 2019, 2, 19.	1.5	30
11	Rosuvastatin pharmacogenetics in African populations. <i>Pharmacogenomics</i> , 2018, 19, 1373-1375.	0.6	3
12	The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. <i>BMC Medical Education</i> , 2018, 18, 233.	1.0	17
13	A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A&gt;C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. <i>BMC Research Notes</i> , 2018, 11, 384.	0.6	4
14	African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. <i>EBioMedicine</i> , 2017, 17, 67-74.	2.7	90
15	Community Based Antiretroviral Treatment in Rural Zimbabwe. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1185-1191.	0.5	11
16	Community burden of undiagnosed HIV infection among adolescents in Zimbabwe following primary healthcare-based provider-initiated HIV testing and counselling: A cross-sectional survey. <i>PLoS Medicine</i> , 2017, 14, e1002360.	3.9	33
17	Practical Approach to Biobanking in Zimbabwe: Establishment of an Inclusive Stakeholder Framework. <i>Biopreservation and Biobanking</i> , 2016, 14, 440-446.	0.5	4
18	Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 498-509.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?. OMICS A Journal of Integrative Biology, 2016, 20, 575-580.	1.0	29
20	Pharmacokinetics of rosuvastatin in 30 healthy Zimbabwean individuals of African ancestry. British Journal of Clinical Pharmacology, 2016, 82, 326-328.	1.1	12
21	Characterisation of artemisinin-chloroquine hybrids for potential metabolic liabilities. Xenobiotica, 2016, 46, 234-240.	0.5	3
22	Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?. PLoS ONE, 2016, 11, e0167852.	1.1	8
23	Biotechnology Innovators To Convene in Cape Town, South Africa: Pharmacogenetics and Precision Medicine Conference (April 7-9, 2016). OMICS A Journal of Integrative Biology, 2015, 19, 731-732.	1.0	0
24	CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacology & Toxicology, 2015, 16, 4.	1.0	61
25	Effect of NIPRISAN® on CYP3A4 activity in vitro. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 115-118.	0.6	5
26	Evaluation of Herbal Medicines: Value Addition to Traditional Medicines Through Metabolism, Pharmacokinetic and Safety Studies. Current Drug Metabolism, 2015, 15, 942-952.	0.7	16
27	The effect of the Pheroid delivery system on their vitrometabolism and in vivo pharmacokinetics of artemisone. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 313-325.	1.5	5
28	Population Diversity and Pharmacogenomics in Africa. , 2014, , 971-998.		8
29	Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 769-785.	1.5	49
30	H3Africa and the African Life Sciences Ecosystem: Building Sustainable Innovation. OMICS A Journal of Integrative Biology, 2014, 18, 733-739.	1.0	40
31	Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1313-1324.	1.5	5
32	Kinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazolium], NAMI-A, by 2-mercaptoethane sulfonate. Dalton Transactions, 2014, 43, 12943-12951.	1.6	7
33	Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe. Current HIV Research, 2014, 11, 481-490.	0.2	13
34	Drug Resistance Mutations from Whole Blood Proviral DNA Among Patients on Antiretroviral Drugs in Zimbabwe. Current HIV Research, 2014, 12, 309-316.	0.2	5
35	The Evaluation of CYP2B6 Inhibition by Artemisinin Antimalarials in Recombinant Enzymes and Human Liver Microsomes. Drug Metabolism Letters, 2013, 6, 247-257.	0.5	9
36	The Metabolism of Antiparasitic Drugs and Pharmacogenetics in African Populations: From Molecular Mechanisms to Clinical Applications. , 2013, , 17-31.		1

#	ARTICLE	IF	CITATIONS
37	Simulation of metabolism-based herb-drug interaction: towards safe and efficacious use of NIPRD-AM1. <i>Avicenna Journal of Phytomedicine</i> , 2013, 3, 201-4.	0.1	2
38	Biotransformation and biocatalysis: roles and applications in the discovery of antimalarials. <i>Future Medicinal Chemistry</i> , 2012, 4, 2325-2336.	1.1	10
39	Pharmacogenomics in Africa. <i>Advances in Microbial Ecology</i> , 2012, , 161-182.	0.1	2
40	Identification and Characterization of Reactive Metabolites in Natural Products-Driven Drug Discovery. <i>Journal of Natural Products</i> , 2012, 75, 507-513.	1.5	29
41	CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 267-271.	0.8	44
42	Extracting molecular information from African natural products to facilitate unique African-led drug-discovery efforts. <i>Future Medicinal Chemistry</i> , 2011, 3, 257-261.	1.1	7
43	Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. <i>Pharmacogenomics</i> , 2009, 10, 1447-1455.	0.6	15
44	Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure Elucidation Using Electrochemistry, Mass Spectrometry, and NMR. <i>Drug Metabolism and Disposition</i> , 2009, 37, 571-579.	1.7	67
45	Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. <i>Human Genomics</i> , 2009, 3, 169.	1.4	80
46	An Experimental Pharmacokinetic Computer Program to Predict Potential Drug-Drug Interactions. <i>The Open Drug Metabolism Journal</i> , 2009, 3, 8-16.	0.5	1
47	High prevalence of the CYP2B6 516Gâ†’T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 357-365.	0.8	176
48	Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 324-334.	1.1	19
49	Electrochemical Generation of Electrophilic Drug Metabolites: Characterization of Amodiaquine Quinoneimine and Cysteinyl Conjugates by MS, IR, and NMR. <i>Chemical Research in Toxicology</i> , 2008, 21, 928-935.	1.7	54
50	Prediction of sites under adaptive evolution in cytochrome P450 sequences and their relationship to substrate recognition sites. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 467-476.	0.7	11
51	Evaluation of the Partec Flow Cytometer against the BD FACSCalibur System for Monitoring Immune Responses of Human Immunodeficiency Virus-Infected Patients in Zimbabwe. <i>Vaccine Journal</i> , 2007, 14, 293-298.	3.2	32
52	The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 29, 70-81.	1.9	105
53	Cytochrome P 450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 537-542.	0.8	36
54	Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 11-17.	0.8	81

#	ARTICLE	IF	CITATIONS
55	In Vitro High Throughput Screening of Compounds for Favorable Metabolic Properties in Drug Discovery.. Combinatorial Chemistry and High Throughput Screening, 2001, 4, 245-263.	0.6	100
56	Arginines 97 and 108 in CYP2C9 Are Important Determinants of the Catalytic Function. Biochemical and Biophysical Research Communications, 2000, 270, 983-987.	1.0	81
57	A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity. British Journal of Clinical Pharmacology, 1996, 42, 713-719.	1.1	189
58	Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe*. Clinical Pharmacology and Therapeutics, 1995, 57, 656-661.	2.3	86